Polymerase Chain Reaction News and Research

RSS

Polymerase chain reaction (PCR) is a revolutionary laboratory technique that enables the replication of a specific DNA sequence. Using PCR, millions of copies of a target DNA can be easily synthesized within a short period of time.

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Reinfection with SARS-CoV-2 in children

These findings bear out earlier reports that COVID-19 is less frequent and severe in children than adults.

7 Jan 2022

SARS-CoV-2 Omicron less pathogenic in hamsters

A new research paper posted as a preprint to the bioRxiv* server attempts to throw some light on this question by studying viral pathogenicity in golden hamsters, a valuable model for severe COVID-19 due to the development of reproducible weight loss and pneumonia after infection with the virus.

6 Jan 2022

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Researchers investigate SARS-CoV-2 antigenic drift by evaluating the neutralizing activity of sera from patients infected with all five SARS-CoV-2 VOCs.

6 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Researchers use statistical models to assess the transmission of the SARS-CoV-2 Omicron using variant-specific screening tests and genome sequencing.

5 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

A recent study reveals early signals of substantially increased vaccine breakthrough for the Omicron variant of SARS-CoV-2 in Houston, Texas.

4 Jan 2022

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

A new research letter assessed patients hospitalized with a positive SARS-CoV-2 test during the fourth wave compared to the previous waves.

4 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

Researchers use data and a mathematical model to determine the impact of the SARS-CoV-2 Omicron variant on future risk of infection.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Omicron surges in England especially in young

Researchers used data from the REACT-1 study to analyze SARS-CoV-2 community prevalence and the emergence of the Omicron variant in England.

3 Jan 2022

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Polymerase Chain Reaction News and Research

Further Reading

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Reinfection with SARS-CoV-2 in children

SARS-CoV-2 Omicron less pathogenic in hamsters

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

How effective are COVID-19 vaccines against the Omicron and Delta variants?

SARS-CoV-2 appears to persist in organs throughout the body for months

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Israeli study confirms drop in BNT162b2 efficacy after six months

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Modeling shows SARS-CoV-2 Omicron will place a severe burden on UK's health services

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Omicron surges in England especially in young

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

SARS-CoV-2 omicron variant may be less severe than the delta variant

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Omicron analysis shows no clear evidence for increased virulence or lethality

MRNA boosters shown to increase protection against SARS-CoV-2 Omicron

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo